Selection pressure exerted by imatinib therapy leads to disparate outcomes of imatinib discontinuation trials
Open Access
- 14 March 2012
- journal article
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 97 (10), 1553-1561
- https://doi.org/10.3324/haematol.2012.062844
Abstract
Chronic myeloid leukemia is successfully managed by imatinib therapy, but the question remains whether treatment must be administered indefinitely. Imatinib discontinuation trials have led to two distinct outcomes: about 60% of patients experienced disease relapse within 6 months of treatment cessation, while the remaining 40% remained disease-free throughout the duration of follow-up. We aimed to investigate the mechanisms underlying these disparate clinical outcomes. We utilized molecular data from the "Stop Imatinib" trial together with a mathematical framework of chronic myeloid leukemia, based on a four-compartment model that can explain the kinetics of the molecular response to imatinib. This approach was complemented by statistical analyses to estimate system parameters and investigate whether chronic myeloid leukemia can be cured by imatinib therapy alone. We found that there are insufficient follow-up data from the "Stop Imatinib" trial in order to conclude whether the absence of a relapse signifies cure of the disease. We determined that selection of less aggressive leukemic phenotypes by imatinib therapy recapitulates the trial outcomes. This postulated mechanism agrees with the observation that most patients who have a complete molecular response after discontinuation of imatinib continue to harbor minimal residual disease, and might work in concert with other factors suppressing leukemic cell expansion when the tumor burden remains low. Our analysis provides evidence for a mechanistic model of chronic myeloid leukemia selection by imatinib treatment and suggests that it may not be safe to discontinue therapy outside a clinical trial.Keywords
This publication has 28 references indexed in Scilit:
- Do we have to kill the last CML cell?Leukemia, 2010
- Successful Therapy Must Eradicate Cancer Stem CellsThe International Journal of Cell Cloning, 2006
- Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implicationsNature Medicine, 2006
- Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapyBlood, 2006
- Bcr-Abl Expression Levels Determine the Rate of Development of Resistance to Imatinib Mesylate in Chronic Myeloid LeukemiaCancer Research, 2005
- Contributions of low molecule number and chromosomal positioning to stochastic gene expressionNature Genetics, 2005
- Dynamics of chronic myeloid leukaemiaNature, 2005
- Stochasticity in gene expression: from theories to phenotypesNature Reviews Genetics, 2005
- Stochastic Gene Expression in a Single CellScience, 2002
- Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid LeukemiaNew England Journal of Medicine, 2001